Gates, other charities pledge $125 million towards COVID-19 treatments


  • World
  • Tuesday, 10 Mar 2020

FILE PHOTO: Bill Gates, Co-Chair of Bill & Melinda Gates Foundation, attends the World Economic Forum (WEF) annual meeting in Davos, Switzerland, January 22, 2019. REUTERS/Arnd Wiegmann/File Photo

CHICAGO (Reuters) - The Bill & Melinda Gates Foundation and two other large charities on Tuesday pledged up to $125 million (£95.57 million) to help speed the development of treatments for the fast-spreading coronavirus, which the World Health Organization said on Monday was nearing pandemic proportions.

The effort, known as the COVID-19 Therapeutics Accelerator, will focus on new and repurposed drugs that can be used right away to treat patients infected with the novel coronavirus and possibly other viruses in the future.

The money is intended to ensure that treatments for the virus will be available in poor countries and affordable for individuals.

Currently, no antiviral drugs or other immune system treatments have been approved to treat COVID-19, the disease caused by the virus.

The Gates Foundation and the Wellcome Trust medical charity are each contributing up to $50 million, and the Mastercard Impact Fund has committed up to $25 million for initial projects.

The Gates Foundation’s funding is part of its $100 million commitment to the COVID-19 response announced last month.

"Viruses like COVID-19 spread rapidly, but the development of vaccines and treatments to stop them moves slowly," Mark Suzman, chief executive officer of the Bill & Melinda Gates Foundation, said in a statement.

"If we want to make the world safe from outbreaks like COVID-19, particularly for those most vulnerable, then we need to find a way to make research and development move faster. That requires governments, private enterprise, and philanthropic organizations to act quickly to fund research and development."

(Reporting by Julie Steenhuysen; Editing by Edwina Gibbs)

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 1
Cxense type: free
User access status: 3
   

Did you find this article insightful?

Yes
No

Across the site